Rossella De Luca

Rossella De Luca

Auto-generated profile, based on publicly available information

Rossella De Luca

Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2011 in European Journal of Histochemistry
Verified
Journal Article
Open access
PDF file
Giovanni TomaselloGiovanni Tomasello
Giovanni Tomasello
CSC. Sciumè
C. Sciumè
Francesca RappaFrancesca Rappa
Francesca Rappa
VRV. Rodolico
V. Rodolico
MZM. Zerilli
M. Zerilli
Francesco CappelloFrancesco Cappello
Francesco Cappello
Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) characterized by damage of large bowel mucosa and frequent extra-intestinal autoimmune comorbidities. The role played in IBD pathogenesis by molecular chaperones known to interact with components of the immune system involved in inflammation is unclear. We previously demonstrated that mucosal Hsp60 decreases in UC patients treated with conventional therapies (mesalazine, probiotics), suggesting that this chaperonin could be a reliable biomarker useful for monitoring response to treatment, and that it might play a role in pathogenesis. In the present work we investigated three other heat shock protein/molecular chaperones: Hsp10, Hsp70, and Hsp90. We found that the levels of these proteins are increased in UC patients at the time of diagnosis and decrease after therapy, supporting the notion that these proteins deserve attention in the study of the mechanisms that promote the development and maintenance of IBD, and as biomarkers of this disease (e.g., to monitor response to treatment at the histological level).

22 June 2016 in La radiologia medica
Verified
Journal Article
Closed access
PDF file
GRGiuseppe Lo Re
Giuseppe Lo Re
RLRossella De Luca
Rossella De Luca
FMFilippa Muscarneri
Filippa Muscarneri
PDPatrizia Dorangricchia
Patrizia Dorangricchia
DPDario Picone
Dario Picone
GCGiuseppe Cicero
Giuseppe Cicero

10 March 2017 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
PDF file
GCGiuseppe Cicero
Giuseppe Cicero
RLR De Luca
R De Luca
PDP Dorangricchia
P Dorangricchia
Gianluca Lo CocoGianluca Lo Coco
Gianluca Lo Coco
CGCinzia Guarnaccia
Cinzia Guarnaccia
ARA Russo
A Russo

1 June 2018 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
RLRossella De Luca
Rossella De Luca
LBLivio Blasi
Livio Blasi
MAMassimiliano Alù
Massimiliano Alù
VGValerio Gristina
Valerio Gristina
GCGiuseppe Cicero
Giuseppe Cicero
Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standard treatments in this cancer increase survival but do not lead to complete recovery of the patient. The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italian patients with metastatic pancreatic cancer (MPC). Patients and methods: We conducted a retrospective analysis of 80 patients. Overall survival (OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combination with gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety, progression-free survival (PFS), overall response rate and reduction in pain were secondary end points. Results: The median OS was 8 months, and the median PFS was 5 months. A considerable difference in CA 19-9 before and after treatment was observed. Descriptive and correlation analyses were done to examine the relationship between CA 19-9 response and OS. Linear regression analysis between OS and CA 19-9 response revealed that CA 19-9 is an important predictor of OS, showing a positive correlation. Conclusion: Nab-paclitaxel is a well-tolerated and effective treatment for patients affected by MPC. The drug showed an improved tolerability profile, significant pain relief and an increase in survival rate.

15 December 2017 in Oncology
Verified
Journal Article
Closed access
PDF file
RLRossella De Luca
Rossella De Luca
RCRenato Patrizio Costa
Renato Patrizio Costa
VTVincenzo Tripoli
Vincenzo Tripoli
AMAlessandra Murabito
Alessandra Murabito
GCGiuseppe Cicero
Giuseppe Cicero
Background/Aim: Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223

1 May 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
GCGiuseppe Cicero
Giuseppe Cicero
RLRossella De Luca
Rossella De Luca
Francesco DieliFrancesco Dieli
Francesco Dieli
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer Giuseppe Cicero,1 Rossella De Luca,1 Francesco Dieli2 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, Palermo, Italy Background: In many clinical trials designed to assess the efficacy of anticancer treatments, overall survival (OS) is often used as a primary endpoint despite its several points of weakness. Methods: This study evaluated the role of progression-free survival (PFS) in the first three lines of treatment as a potential surrogate endpoint of OS in patients with metastatic colorectal cancer (MCRC). One hundred and twenty patients with MCRC were enrolled in this study. The median PFS of the first-, second-, and third-lines of treatment and the OS were evaluated. The correlation between the time to progression and the OS was analyzed. The median PFS of the three lines of treatment were 8.5, 5, and 3 months, respectively. Results: The median OS was 32.4 months. A modest correlation was found between the PFS to the first-line treatment with Folfox–avastin and OS. Similar data were obtained with the second-line treatment. However, no correlation was found between the PFS and OS during the third-line treatment. The regression analysis revealed that PFS is predictive of OS. Conclusion: In brief, the PFS of the first- and second-lines of treatment could be a good candidate as a surrogate endpoint of OS in patients with MCRC. Keywords: colorectal neoplasm, overall survival, progression-free survival, surrogate endpoint liver metastates, avastin, egorafenib